**8. Conclusions**

As observed in clinical studies, the greatest advantage of delpazolid over linezolid is the potential for delpazolid to be used in long-term therapies. The development of delpazolid has focused on TB treatment, as this disease requires long-term treatment. In December 2016, LegoChem Biosciences entered into a license agreement with RMX Biopharma for the development, manufacture, and commercialization of delpazolid in China. In addition, delpazolid received an FDA orphan drug designation, a Qualified Infectious Disease Product Designation, and was selected as a Fast Track target drug.

On October 30, 2019, at 'The 50th Union World Conference on Lung Health,' held in Hyderabad, India, LegoChem Biosciences released the interim efficacy and safety results of a phase 2a study on delpazolid. Particularly, the results of a clinical phase 2a early bactericidal activity trial involving 79 Korean patients with drug-susceptible tuberculosis were reported. The findings will be further analyzed to determine the doses appropriate for different patient populations to guide further phase 2a studies. The phase 1 trial revealed that myelosuppression can be reduced, and phase 2a results suggested that delpazolid can replace linezolid as a therapy for TB and reduce the treatment period.

**Author Contributions:** Conceptualization, Y.L.C. and J.J.; writing, J.J.; review and editing, Y.L.C. and J.J.; visualization, Y.L.C. and J.J.; project administration, Y.L.C. and J.J. All authors have read and agreed to the published version of the manuscript.

**Acknowledgments:** We thank all those who provided important information that was part of this work. We also thank Tae ho Kim for his assistance in figure preparation.

**Conflicts of Interest:** The authors declare no conflict of interest.
